Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury

Biomarkers in Medicine

Volumn 7, Issue 2, 2013, Pages 307-315

  Shi, Qiang ^a   Yang, Xi ^a   Mendrick, Donna L ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

acetaminophen; biomarker; DILI; drug induced liver injury; hepatotoxicity; miRNA

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; DOXORUBICIN; METHAPYRILENE; MICRORNA; MICRORNA 122; MICRORNA 22; PARACETAMOL; PARAQUAT; PENICILLIN DERIVATIVE; PHENOBARBITAL;

ANIMAL EXPERIMENT; BLOOD LEVEL; CLINICAL RESEARCH; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE MODEL; FATALITY; HUMAN; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TOXIC HEPATITIS;

ANIMALS; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; HUMANS; MICRORNAS; PROTEIN BIOSYNTHESIS;

ANIMALIA;

EID: 84875826688     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.9     Document Type: Review

References (47)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998). (Pubitemid 28193431)
2. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J. Hepatol. 33(6), 949-952 (2000).
3. Navarro VJ, Senior Jr. Drug-related hepatotoxicity. N. Engl. J. Med. 354(7), 731-739 (2006). (Pubitemid 43247143)
4. Tarantino G, Conca P, Basile V et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol. Res. 37(6), 410-415 (2007). (Pubitemid 46915785)
5. Shi Q, Hong H, Senior J, Tong W. Biomarkers for drug-induced liver injury. Expert Rev. Gastroenterol. Hepatol. 4(2), 225-234 (2010).
6. Mendrick DL, Daniels KK. Biomarkers of drug-induced adverse events. Expert Rev. Clin. Pharmacol. 1(1), 81-91 (2008).
7. Sun W, Julie Li YS, Huang HD, Shyy JY, Chien S. microRNA: a master regulator of cellular processes for bioengineering systems. Annu. Rev. Biomed. Eng. 12, 1-27 (2010).
8. Tung J. Exploring microRNA biomarkers for disease monitoring and response to therapy. Bioanalysis 4(18), 2204 (2012).
9. Yokoi T, Nakajima M. microRNAs as mediators of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 53, 377-400 (2012).
10. Wang K, Zhang S, Marzolf B et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl Acad. Sci. USA 106(11), 4402-4407 (2009).
11. Starkey Lewis PJ, Merz M, Couttet P et al. Serum microRNA biomarkers for drug-induced liver injury. Clin. Pharmacol. Ther. 92(3), 291-293 (2012).
12. Starkey Lewis PJ, Dear J, Platt V et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54(5), 1767-1776 (2011).
13. Bala S, Petrasek J, Mundkur S et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 56(5), 1946-1957 (2012).
14. Su YW, Chen X, Jiang ZZ et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound-and herb-induced liver injury in rats. PLoS ONE 7(5), e37395 (2012).
15. Jaeschke H, Mcgill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab. Rev. 44(1), 88-106 (2012).
16. Lee WM. Acute liver failure. Semin. Respir. Crit. Care Med. 33(1), 36-45 (2012).
17. Ward J, Bala S, Petrasek J, Szabo G. Plasma microRNA profiles distinguish lethal injury in acetaminophen toxicity: a research study. World J. Gastroenterol. 18(22), 2798-2804 (2012).
18. Starckx S, Batheja A, Verheyen GR et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol. Pathol. doi:10.1177/0192623312464436 (2012) (Epub ahead of print).
19. Yamaura Y, Nakajima M, Takagi S, Fukami T, Tsuneyama K, Yokoi T. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS ONE 7(2), e30250 (2012).
20. Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure. J. Pediatr. Gastroenterol. Nutr. 47(4), 395-405 (2008).
21. Zhang Y, Jia Y, Zheng R et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 56(12), 1830-1838 (2010).
22. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment. Pharmacol. Ther. 37(1), 3-17 (2013).
23. Tarantino G, Pezzullo MG, Di Minno MN et al. Drug-induced liver injury due to "natural products" used for weight loss: a case report. World J. Gastroenterol. 15(19), 2414-2417 (2009).
24. Ding X, Ding J, Ning J et al. Circulating microRNA-122 as a potential biomarker for liver injury. Mol. Med. Report 5(6), 1428-1432 (2012).
25. Yun SJ, Jeong P, Kim WT et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int. J. Oncol. 41(5), 1871-1878 (2012).
26. Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. Clin. J. Am. Soc. Nephrol. 7(9), 1528-1533 (2012).
27. Yang X, Greenhaw J, Shi Q et al. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol. Sci. 125(2), 335-344 (2012).
28. Lewis AP, Jopling CL. Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 38(6), 1553-1557 (2010).
29. Lindow M, Kauppinen S. Discovering the first microRNA-targeted drug. J. Cell. Biol. 199(3), 407-412 (2012).
30. Laterza OF, Lim L, Garrett-Engele PW et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin. Chem. 55(11), 1977-1983 (2009).
31. Bushel PR, Heinloth AN, Li J et al. Blood gene expression signatures predict exposure levels. Proc. Natl Acad. Sci. USA 104(46), 18211-18216 (2007). (Pubitemid 350210846)
32. Umbright C, Sellamuthu R, Li S, Kashon M, Luster M, Joseph P. Blood gene expression markers to detect and distinguish target organ toxicity. Mol. Cell. Biochem. 335(1-2), 223-234 (2010).
33. Jetten MJ, Gaj S, Ruiz-Aracama A et al. 'Omics analysis of low dose acetaminophen intake demonstrates novel response pathways in humans. Toxicol. Appl. Pharmacol. 259(3), 320-328 (2012).
34. Gilad S, Lithwick-Yanai G, Barshack I et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. J. Mol. Diagn. 14(5), 510-517 (2012).
35. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 1820(7), 940-948 (2012).
36. Jopling C. Liver-specific microRNA-122: biogenesis and function. RNA Biol. 9(2), 137-142 (2012).
37. Corsini A, Ganey P, Ju C et al. Current challenges and controversies in drug-induced liver injury. Drug Saf. 35(12), 1099-1117 (2012).
38. Lee WM, Senior Jr. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol. Pathol. 33(1), 155-164 (2005). (Pubitemid 40216814)
39. Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J. Gastroenterol. 15(23), 2817-2833 (2009).
40. Pritchard CC, Kroh E, Wood B et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila.) 5(3), 492-497 (2012).
41. Qi R, Weiland M, Gao XH, Zhou L, Mi QS. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology 55(5), 1640-1642; author reply 1642-1643 (2012).
42. Lardizabal MN, Nocito AL, Daniele SM, Ornella LA, Palatnik JF, Veggi LM. Reference genes for real-time PCR quantification of microRNAs and messenger RNAs in rat models of hepatotoxicity. PLoS ONE 7(5), e36323 (2012).
43. Thulin P, Rafter I, Stockling K et al. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol. Appl. Pharmacol. 231(1), 1-9 (2008).
44. Goodsaid FM, Mendrick DL. Translational medicine and the value of biomarker qualification. Sci. Transl Med. 2(47), 47ps44 (2010).
45. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 6(6), e20769 (2011).
46. Rockey DC, Seeff LB, Rochon J et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51(6), 2117-2126 (2010).
47. Garcia-Cortes M, Stephens C, Lucena Mi, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J. Hepatol. 55(3), 683-691 (2011).